ADX-038 is under clinical development by ADARx Pharmaceuticals and currently in Phase I for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase I drugs for Paroxysmal Nocturnal Hemoglobinuria have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADX-038’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ADX-038 overview

ADX-038 is under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The therapeutic candidate is a siRNA duplex oligonucleotide which is being developed based on RNA Targeting Technology.

ADARx Pharmaceuticals overview

ADARx Pharmaceuticals (ADARx) is a genetic medicine company that edits messenger RNA targeting transcripts and oligonucleotide-based therapies. The company develops therapies in therapeutic areas of genetic, cardiometabolic, and central nervous system (CNS) diseases. It offers proprietary ribonucleic acid targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies, a growing pipeline of ribonucleic acid targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated, and central nervous system diseases, enabling patients to treat incurable diseases . The company operates in the US. ADARx is headquartered in San Diego, California, the US.

For a complete picture of ADX-038’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.